摘要
背景与目的已有的研究表明,肝素酶与Ki-67抗原与肺癌的发生和转移有关,本研究通过检测非小细胞肺癌(Non-small cell lung cancer,NSCLC)组织中肝素酶(heparanase,Hpa)和Ki-67的表达,以探讨他们的临床意义及相互关系。方法采用免疫组化方法(S-ABC法和S-P法)检测70例NSCLC和20例同期良性病变肺组织中肝素酶和Ki-67的表达。结果肝素酶和Ki-67的阳性表达率分别为72.9%和85.7%,而正常肺组织中两者均无表达;肝素酶表达水平与患者TNM分期及淋巴结转移有关(P=0.044,P=0.001);Ki-67的表达水平与原发肿瘤大小、组织学类型、癌细胞分化程度、淋巴结转移及TNM分期有关(P<0.05);肝素酶和Ki-67的表达差异无统计学意义(P=0.323)。结论肝素酶和Ki-67参与了肺癌的发生和发展,并与预后相关;而肝素酶和Ki-67的表达无相关性,两者可能通过不同的机制参与了肿瘤的发生和发展。
Background and objective It has been proven that heparanase and Ki-67 had relationship with occurrence and metastasis in lung cancer. The aim of this work was to investigate the expressions ofheparanase and Ki-67 and to explore their clinical significance and mutual relations in non-small cell lung cancer （NSCLC）. Methods Immunohistochemical method was used to detect the heparanase and Ki-67expression in the routinely paraffin-embedded sections of surgical specimen of 70 cases with NSCLC and 20 ones with normal lung tissues. Results Heparanase and Ki-67 were highly expressed in lung cancer tissues （72.9% and 85.7%） while negative in epithelia of normal lung tissues. The expression of heparanase was significantly correlated with TNM stage （P=0.044） and lymphatic metastasis （P=0.001）. The expression of Ki-67 was significantly correlated with tumor size （P=0.03） and histology type （P=0.001 ） and differentiation （P=0.01） and lymphatic metastasis （P=0.01） and TNM stage （P=0.043）. The expression ofheparanase and Ki-67 was no significant difference （P=0.323）. Conclusion Heparanase and Ki-67 were involved in the occurrence and development ofhmg cancer and they may predict patients prognosis, while the expression of heparanase and Ki-67 had no association with NSCLC, which may contribute to the different mechanisms involved in tumor occurrence and development.
出处
《中国肺癌杂志》
CAS
2009年第7期785-788,共4页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
肝素酶
KI-67
免疫组化
Lung neoplasms
Heparanase
Ki-67
Immunohistochemistry
